News
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...
At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...
Mumbai: In a serious security and public health concern, several consignments of Novo Nordisk’s injectable medicines — ...
COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results